Keros Therapeutics (NASDAQ:KROS) Hits New 12-Month Low - Here's What Happened

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as $12.35 and last traded at $12.82, with a volume of 2313529 shares. The stock had previously closed at $14.56.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KROS. Wedbush reiterated an "outperform" rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, December 12th. Wells Fargo & Company upped their target price on Keros Therapeutics from $88.00 to $111.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th. Scotiabank reduced their price target on shares of Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating for the company in a research report on Friday, December 13th. Finally, William Blair cut shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $70.56.

Keros Therapeutics Stock Performance

The stock has a market cap of $418.06 million, a PE ratio of -2.00 and a beta of 1.43. The company's 50-day moving average price is $39.77 and its 200 day moving average price is $47.88.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics's revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) EPS. On average, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

A number of large investors have recently added to or reduced their stakes in KROS. Geode Capital Management LLC increased its holdings in shares of Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock valued at $42,146,000 after acquiring an additional 46,041 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Keros Therapeutics by 14.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company's stock valued at $15,105,000 after acquiring an additional 32,492 shares during the period. Barclays PLC boosted its position in Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after purchasing an additional 35,022 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Keros Therapeutics during the 3rd quarter worth approximately $603,000. Finally, Point72 Asset Management L.P. boosted its holdings in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after buying an additional 577,220 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.